Sotrovimab: Abu Dhabi first in the world to receive new Covid treatment drug
The anti-viral treatment has shown to prevent severe illness and death in 85 per cent of cases treated early.
The world’s newest anti-viral treatment for Covid-19, Sotrovimab, is now available for early treatment of certain categories Covid-19 patients in the UAE following a landmark agreement between the Abu Dhabi Department of Health, the country’s leading group purchasing organization (GPO) Rafed, and global innovative biopharmaceutical company GlaxoSmithKline (GSK). With the arrival of the first shipment in Abu Dhabi airport, Abu Dhabi become the first city globally to receive this drug.
Sotrovimab is a monoclonal antibody treatment delivered through intravenous therapy. Sotrovimab can be used to treat adults and children above the age of 12 who meet certain criteria and are at risk of progressing to severe Covid-19, as per protocols that have been developed by the National Scientific Committee. Studies have shown the medicine to prevent hospitalization and death in 85 per cent of early selected treatment cases and can work on all known variations to date, a statement issued on Wednesday said.
Following USA Food and Drug Agency Emergency use authorization approval, the UAE Ministry of Health and Prevention (MoHAP) issued its endorsement of the new GSK medicine following a national assessment. Abu Dhabi Department of Health & Rafed executed its agreement with the manufacturer to ensure deliveries as early as June and July, enabling patients in the UAE to be among the first in the world to access the new therapy.
The National Scientific Committee in MoHAP & Abu Dhabi Department of Health have worked on the treatment protocols that will guide doctors in defining at risk patients and ensuring that they have access to Sotrovimab according to their risk profile and eligibility criteria.
Abu Dhabi-based Rafed will facilitate the procurement, storage and distribution of Sotrovimab via the Rafed Distribution Center - the Region’s largest specialised cold-storage facility. The Center is part of the Hope Consortium, and is a milestone collaboration by healthcare, logistics and supply chain entities designed to facilitate the ongoing evolution of Abu Dhabi’s medical and life science offering to combat the pandemic, nationally and internationally
HE Dr. Jamal Mohamed Kaabi, Undersecretary for the Abu Dhabi Department of Health, said: “Abu Dhabi continues in its efforts to maintain its number one city position globally in terms of resilience and safety in Covid-19 times. This medicine is at the forefront of pharmaceutical advancement and is a powerful tool in our fight to end this pandemic.
"We look forward to implement the eligibility criteria for emergency use of Sotrovimab as part of Abu Dhabi’s commitment to lead an all-encompassing Covid -19 response in prevention, treatment and care.”
Rashed Al Qubaisi, CEO of Rafed said: “Sotrovimab represents a massive breakthrough in the fight against COVID-19."
As the Department of Health – Abu Dhabi finalises a coherent framework to determine eligibility for Sotrovimab treatment, Etihad Cargo, the cargo and logistics arm of the Etihad Aviation Group and Hope Consortium, have transported the first batch of Sotrovimab into the UAE utilizing its IATA CEIV-certified PharmaLife product.
Tony Douglas, Group Chief Executive Officer, Etihad Aviation Group, said: “This achievement further elevates Abu Dhabi’s leading position in the fight against Covid-19, and firmly illustrates the combined capabilities of those entities at the forefront of the capital’s mission.
After receiving positive scientific opinion by the European Medicines Agency’s (EMA) Committee for Human Medicinal Products - GSK had submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration and the UAE Ministry of Health and Prevention and got approval from both.
“We have been working very closely with the Department of Health and Rafed since the interim results of the clinical trials with Sotrovimab were available” said Gizem Akalin, Managing Director and Vice President, GSK Gulf. “The DOH and Rafed have been agile and passionate about accelerating patient access to promising new treatments to confront Covid-19”.
It was unclear whether the new testing requirements would apply to... READ MORE
Singapore has inoculated 75% of its population with at least one dose. READ MORE
'The second time was much worse than the first' READ MORE
New cases include two athletes. READ MORE
The decision will go into effect from Sunday, September 19 READ MORE
The decision follows the announcement of a decreased Covid-19... READ MORE
In a brief public statement, Prime Minister Jacinda Ardern said the... READ MORE
Medical experts also want health care workers and people at high risk ... READ MORE